# Transfusion and Cross-Matching

#### BY:

Dr. Osamah T. Khojah, mbbs, ms. Med, Ms. Sc, KSUF, IFCAP
Assistant Professor

Hematopathologist and Transfusionist
Department of Pathology
<a href="mailto:asd@ksu.edu.sa">asd@ksu.edu.sa</a>, 0555485892

# LEARNING OBJECTIVES

- > To identify the key elements in the current blood bank services.
- ➤ To appreciate the implemented measurements and standards for obtaining the highest quality in the blood bank services.
- To have a general idea about the donation process and main blood components.
- > To understand the inheritance and significance of the ABO system.
- > To understand the nature and significance of the Rh blood group system.
- > To understand the cross-matching process, including the antiglobulin test.
- > To have an overview about main hazards of blood transfusion.

## **Blood Bank Units**

- ▶ Traditionally, two parts:
  - ▶ 1) **Donation services**: donor area, component separation, infectious testing, ABO typing and RhD screening, inventory.
  - 2) Transfusion services: inventory, Patient (recipient) ABO grouping, RhD and antibody identification screening, crossmatch, component issuing.
- Currently in the major hospital, there is a **apheresis** unit (donation, therapeutic or prophylaxis).
- In many tertiary hospitals, stem cell unit, cord blood unit and tissue banking.



## **Donor Selection**

TABLE 5-1. Physical Examination and Requirements for Allogeneic and Autologous Whole-Blood Donation

	Allogeneic AABB Reference Standard 5.4.1A; Title 21, CFR Part 640.3	Autologous AABB Standard 5.4.4; Title 21, CFR Part 640.3	
Age	Conform to applicable state law or ≥10 years	Alternate requirements defined by blood center's medical director (AA Standard 5.4.4).	
Blood pressure	No requirement in AABB standards, systolic and diastolic blood pressure "within normal limits" [Title 21, CFR Part 3(2)].		
Pulse	No requirement in AABB standards or CFR.	_	
Whole blood vol- ume collected	Maximum of 10.5 mL/kg of donor weight, including samples.	_	
Donation interval	8 weeks after whole blood donation; 10 weeks after 2-unit red cell collection; 4 weeks after infrequent plasmapheresis; and ≥2 days after plasma-, platelet-, or leukapheresis.	_	
Temperature	≤37.5 C (99.5 F) if measured orally or equivalent if measured by another method.	Deferral for conditions presenting risk of bacteremia (AABB Standard 5.4.4.4).	
Hemoglobin (hematocrit)	≥12.5 g/dL (≥38%).	≥11 g/dL (≥33%).	

## Table 30.1 Measures used to protect the donor and for donor selection.

Donor selection

Age 17-70 years (maximum 65 at first donation)

Weight above 50kg (7st 12lb)

Haemoglobin >134 g/L for men, >120 g/L for women

Minimum donation interval of 12 weeks (16 weeks advised) and three donations per year maximum

Apheresis for platelets or plasma up to 24 times in 12 months

Pregnant and lactating women excluded because of high iron requirements; donation deferred for 9 months post pregnancy

Exclusion of those with:

Known cardiovascular disease, including hypertension

Significant respiratory disorders

Epilepsy and other CNS disorders

Gastrointestinal disorders with impaired absorption

Previous blood transfusions in the UK

Intravenous drug users

Insulin-dependent diabetes

Chronic renal disease

Cancer

Ongoing medical investigation or clinical trials

Exclusion of those with:

Known cardiovascular disease, including hypertension

Significant respiratory disorders

Epilepsy and other CNS disorders

Gastrointestinal disorders with impaired absorption

Previous blood transfusions in the UK

Intravenous drug users

Insulin-dependent diabetes

Chronic renal disease

Cancer

Ongoing medical investigation or clinical trials

Exclusion of any donor returning to occupations such as driving bus, plane or train, heavy machine or crane operator, mining, scaffolding, etc. because delayed faint would be dangerous

Defer for 12 months after body piercing or tattoo, paid sex or homosexual sex, after acupuncture

Defer for 2 months after live vaccinations such as measles, mumps

Defer if travel history suggests risk of infection





#### DONOR HEALTH HISTORY QUESTIONNAIRE REGESTRATION

Donor No.:	Date:		Date:		No.:
أسم المتبرع Donor Name					
العائلة:		الجد:		الأب:	الأسم الاول:
First Name:	Father Name:		Middle Name:	exism lenoi	Family Name:
Date of last donation:			Place of la	st donation:	EDV DVDR ABBRADDEL CONST
Result of last donation:	may It CV/	EBY	V 2011-30 5030	8 28 Maga	STATE OF STA
Gender: Male	Female		Nationality:	E your lawy o	WENT CHIEF AT LEAST OF A SEC.
Date of birth: /	1	Age:	years		Charles Comment of
Passport Iqama	] ID [	N	o.:	on on a en	sector de traine final 3
Address:					and a sharp are a
Mobile:	Tandoon cal	liedųs ne p	Phone:	Lotte Unit of	2. Have you donated a don
E- Mail :				kuta ierto	o ancilnologay yas barl .b
		Donation Res	سببالتبرع on		
متطوع 🗌 Volunteer	The	rapeutic	علاجي	Repal	ement موجه الريض
ذاتي 🗌 Autologous	Driving	g License	ستخراج رخصة	1	
Patient File No.:		- VOLUMENT	MINERS TO TARRE		رقم ملف المريض:
		Type of dona	نوع التبرع ation		
Whole blood       وحدة كاملة       Plasma Aphaeresis       الازما         Automated Double R. B. C.       وحدة مزدوجة من خلايا الدم الحمراء       Platelets Aphaeresis       Platelets Aphaeresis					
THIS SECTION TO BE COMPLETED BY FRIST-TIME DONORS ONLY					
HAVE YOU EVER RECEIVED BLOOD ? YES NO UNKNON					
CURRENT OCCUPATION:					
HOW WOULD YOU PREFEER TO BE Letter Mobile Email Fax  REMINDED TO DONATE BLOOD? Phone SMS None					
Receptionist:				Signature	e: ne seider never need 21

- Powerful tool for screening
- Identify high risk behaviors.
- Some issues can only be ruled out by systemic questionnaire.

# Infectious Testing

#### Table 30.2 Donor testing in England and Wales.

- 1 Blood group, Rh status (D,C,E,c,e), K
- Screen for red cell alloantibodies
- 3 Microbiological tests

Human immunodeficiency virus (HIV) 1 and 2; antibody and RNA

Hepatitis B virus (HBV) - antibody and RNA

Hepatitis C virus (HCV) – antibody and RNA

Human T-cell leukaemia viruses (HTLV) – antibody


Cytomegalovirus (CMV) – antibody, for immunosuppressed recipients

Malaria – antibody screening of potentially exposed donors Chagas' disease – antibody screening of potentially exposed donors

Bacteria – all donations tested for antibody to syphilis

N.B. At the current time there is no reliable test for detecting prions in blood products.

- Extra testing (not in all cases);
- Sickle cell.
- G6PD level.



# **Component Separation**





Figure 30.1 The preparation of blood components from whole blood. FFP, fresh frozen plasma; SAGM, saline-adenine-glucose-mannitol.

\* Cryoprecipitate is mainly a source of fibrinogen. Cryosupernatant is used for plasma exchange in thrombotic thrombocytopenic purpura.

Leucodepletion – see text.



# Component

Table 1: Storage Details for Various Blood Products					
Product	Storage	Product	Storage		
RBCs / Whole blood	35 days (CPDA-1) 42 days (Additives) 1-6 C	Granu- locytes	24 hours; 20-24 C (no agitation)		
Frozen RBCs		Fresh Frozen	1 year; -18 C OR 7 years, -65 C;		
r rozen KBCs	10 years; -65 C; 24 hours after thaw	Plasma	24 hours at 1-6 C		
Washed RBCs	24 hours; 1-6 C	CRYO	after thaw 1 year at -18 C		
Platelets	5 days; 20-24 C (gentle agitation); 4 hours if pooled		6 hours at 20-24 C after thaw (4 hours if pooled)		

## Whole blood

- 1. The original blood product!
- 2. Minimal availability in most blood banks today
- 3. Specifics:

Volume: 450-500 mL
Contents: RBCs (200-250 mL)
Plasma (250-300 mL)
WBCs (109)
Platelets
Anticoagulant (63 or 70 mL)

Volume: 40-60 mL Contents: PLTs ( $\geq 5.5 \times 10^{10}$  in 90%) Plasma (40-60 mL) WBCs (10<sup>7</sup>) pH  $\geq 6.2$  (90%)

Whole blood donor (5-6 pooled)

Volume: 200-250 mL

Contents: All coag factors
- 400 mg fibrinogen
- 1 IU/mL of all others
Almost no viable WBCs
NOTE: No QC testing

Fresh Frozen Plasma (FFP)

## Specifics: Packed RBC unit

# Volume: 350 mL (incl. additive) Contents: RBCs (200-250 mL) Without Plasma (≤ 50 mL) Wellower WBCs (109) and PLTs duction Anticoagulant (63 or 70 mL) Additive solution 200-250 mg iron

## Single donor (apheresis) adult dose

Volume: 100-150 mL (or more)

Contents: PLTs (≥ 3.0 x 10<sup>11</sup> in 90%)


Plasma (100-150 mL)

WBCs ( $< 5.0 \times 10^6$ ) pH  $\ge 6.2 (90\%)$ 


## Cryoprecipitate

Volume: 15 mL
Contents: ≥ 150 mg fibrinogen
≥ 80 IU Factor VIII
80-120 IU vWF

80-120 IU vWF 40-60 IU Factor XIII Fibronectin




## **Transfusion Unit**



# **Blood Groups**

- \* One of the main problems in the transfusion of blood is the avoidance of <u>immunological reactions</u> resulting from the differences between donor and recipient red cells.
- \* When the red cells of a donor are transfused into a recipient who lacks these **antigens**, they may induce an immunological response.

\* There are at least 30 major blood group systems (e.g. the ABO group, Rh group).



## Table 30.3 Clinically important blood group systems.

Systems	Frequency of antibodies	Cause of haemolytic transfusion reaction	Cause of haemolytic disease of newborn
ABO	Almost universal	Yes (common)	Yes (usually mild)
Rh	Common	Yes (common)	Yes
Kell	Occasional	Yes (occasional)	Anaemia not haemolysis
Duffy	Occasional	Yes (occasional)	Yes (occasional)
Kidd	Occasional	Yes (occasional)	Yes (occasional)
Lutheran	Rare	Yes (rare)	No
Lewis	Occasional	Yes (rare)	No
Р	Occasional	Yes (rare)	Yes (rare)
MN	Rare	Yes (rare)	Yes (rare)
Li	Rare	Unlikely	No


# ABO system

- Practically all red cells have the <u>H antigen</u>, a carbohydrate group attached mainly to proteins on the cell membrane (FUT1, Ch19q).
- This H antigen is the basis for the ABO blood groups.
- The ABO locus is encoded on chromosome 9q, where one of three possible alleles may be found.
- The **A allele** encodes for a glycosyltransferase, which modifies the H antigen by adding **N-acetylgalactosamine** to it (thus forming the A antigen).

### cont'd...

- The **B** allele of the ABO locus encodes an alternative glycosyltransferase that links **galactose** to the H antigen (thus converting it to the B antigen).
- The O allele, by contrast, encodes no functional enzyme at all, such that the H antigen remains unmodified.

• <u>Hemolytic reactions</u> will occur **immediately** in the event of incompatible transfusion, and may be fatal.



	Group A	Group B	Group AB	Group O
Red blood cell type		- B	AB	
Antibodies in Plasma	Anti-B	Anti-A	None	Anti-A and Anti-B
Antigens in Red Blood Cell	♥ A antigen	† B antigen	••• A and B antigens	None

Phenotype	Genotype	Antigens	Naturally occurring antibodies	Frequency (UK) (%)
0	00	0	Anti-A, anti-B	46
Α	AA or AO	Α	Anti-B	42
В	BB or BO	В	Anti-A	9
AB	AB	AB	None	3

Type	Whites	Blacks	Asians	Native Americans
0	45%	49%	40%	79%
$\mathbf{A}$	40%	27%	28%	16%
В	11%	20%	27%	4%
AB	4%	4%	5%	<1%




Figure 30.3 (a) The ABO grouping in a group A patient. The red cells suspended in saline agglutinate in the presence of anti-A or anti-A + B (serum from a group O patient). (b) Routine grouping in a 96-well microplate. Positive reactions show as sharp agglutinates; in negative reactions the cells are dispersed. Rows 1–3, patient cells against antisera; rows 4–6, patient sera against known cells; rows 7–8, anti-D against patient cells.

# Rh system

- The Rh system is also of great importance and can cause problems with both transfusion and pregnancy. The inheritance of the Rh blood group system is slightly more complex than that of the ABO system.
- Two separate genetic loci on chromosome 1 encode for a total of five antigens.
- The first locus, *RHD*, has alleles D or d; D encodes a transmembrane protein featuring the D antigen, while the allele d encodes a variant that does not bear this antigen.
- *RHCE* is an adjacent locus that encodes a transmembrane ion channel bearing the antigens C (or its variant, c) and E (or its variant, e). Alleles at this locus may be described as CE, Ce, cE and ce, denoting the set of antigens they encode.
- A complete description of the Rh haplotype for a patient will include alleles at both *RHD* and RHCE loci. The commonest haplotypes are DCe, dce and DcE.

#### cont'd...

- The D antigen is the most clinically important of the Rh group antigens, due to its high immunogenicity.
- An RhD-negative person (e.g. dce/dce) has over a 50% chance of developing anti-D antibodies after the transfusion of one unit of RhD-positive blood: it is therefore important that RhD-negative patients receive RhD-negative blood.
- Note that unlike the ABO system, Rh antibodies are not naturally occurring; they must be raised by exposure of an antigen-negative individual to the appropriate antigen, either through transfusion of incompatible blood or through pregnancy.
- After the exposure, IgG antibodies come to predominate, and hemolysis is generally extravascular (major cause of HDFN/HDN).




Figure 30.4 Molecular genetics of the Rh blood group. The locus consists of two closely linked genes, RhD and RhCcEe. The RhD gene codes for a single protein which contains the RhD antigen whereas RhCcEe mRNA undergoes alternative splicing to three transcripts. One of these encodes the E or e antigen whereas the other two (only one is shown) contain the C or c epitope. A polymorphism at position 226 of the RhCcEe gene determines the Ee antigen status whereas the C or c antigens are determined by a four amino acid allelic difference. Some individuals do not have an RhD gene and are therefore RhD—.

Table 30.5 The most common Rh genotypes in the UK population.				
Short symbol	Frequency in white people (%)	Rh D status		
₽r	15	Negative		
R,r	31	Positive		
R,R,	16	Positive		
R <sub>2</sub> r	13	Positive		
R <sub>1</sub> R <sub>2</sub>	13	Positive		
$R_2R_2$	3	Positive		
	9	Positive (almost all)		
	Short symbol  R r R r R r R R R R R R R R R R R R R	Short symbolFrequency in white people (%) $\mathbf{A}r$ 15 $\mathbf{R}_1\mathbf{r}$ 31 $\mathbf{R}_1\mathbf{R}_1$ 16 $\mathbf{R}_2\mathbf{r}$ 13 $\mathbf{R}_1\mathbf{R}_2$ 13 $\mathbf{R}_2\mathbf{R}_2$ 3		

## Management of mother and child

- Women who are negative for RhD are given routine antenatal anti-D prophylaxis at 28 weeks, 34 weeks and within 72 hours of delivery.
- This involves an intramuscular injection of anti-D immunoglobulin, which prevents active immunization in the case of red cell transfer across the placenta.
- Any potentially sensitizing event is also treated with additional anti-D administration: such events include abdominal trauma, threatened abortion, or any spontaneous abortion after 12 weeks.

# Other blood group systems

- ▶ Other blood group antibodies, which are sometimes a problem during blood transfusion, include the following:
  - > anti-K (Kell system),
  - > anti-Fy<sup>a</sup> (Duffy system),
  - > anti-Jk<sup>a</sup> (Kidd system) and
  - > anti-S (part of the MNSs blood group system).
- ▶ These antigens are relatively poorly immunogenic.
- ► Their potency in stimulating antibody production is 10-1000 times less than that of RhD.
- Consequently, these antigens may not need be routinely assessed prior to transfusion.

# Compatibility

• The purpose of **cross-matching** blood before transfusion is to ensure that there is no antibody present in the recipient's plasma that will react with any antigen on the donor's cells (major cross-match, IAT).

• The basic technique for detecting such antibodies relies on their ability to agglutinate red cells that bear the appropriate antigen.

# Antiglobulin test

❖ Its purpose is to detect antibodies to red cell surface, either bound to the red cell surface or free in the serum.

- \* The antiglobulin test can be used in two ways:
  - ▶ First, the <u>direct antiglobulin test</u>, used in the diagnosis of autoimmune hemolytic anemia. it can be used to detect antibody already on the patient's cells *in vivo*. Red cells are washed to remove the free IgG in the plasma, which would otherwise react with and neutralize the antiglobulin. After washing, anti-human globin is added and, if the red cells are coated with antibody, agglutination takes place.

#### cont'd...

▶ Second, *the* <u>indirect antiglobulin test</u>, the test can be used to detect the presence of antibody in serum, as in the cross-matching of blood for transfusion. In this case, serum from the patient who requires transfusion is incubated with donor red cells. Any antibody present in the recipient's serum that has specificity for antigens on the donor's cells will interact with those cells. After washing, addition of antihuman globulin will bring about red cell agglutination.




Image credit: Zarandona JM and Yazer MH. The role of the Coombs test in the evaluation of hemolysis in adults. Canadian Medical Association Journal 2006;174:305-307

### Hazards of blood transfusion:

the Serious Hazards of Transfusion (SHOT) Committee, between 1996 and 2010.




Figure 15.1 Pie chart showing hazards of transfusion in the UK from 1996-2010 as reported to the SHOT Committee. *Notes:* TRALI - transfusion-associated acute lung injury; TTI - transfusion-transmitted infection; ATR - acute transfusion reaction; DTR - delayed transfusion reaction; PTP - post-transfusion purpura; IBCT - incorrect blood component transfused

Source: UK SHOT Committee report 2010.

#### Table 30.6 Measures to protect recipient.

Donor selection (see Table 30.1)

Donor deferral/exclusion (see Table 30.1)

Stringent arm cleaning

Microbiological testing of donations (Table 30.2)

Immunohaematological testing of donations

Discarding the first 20-30 mL of blood collected

Leucodepletion of cellular products

Post-collection viral inactivation of FFP

Monitoring and testing for bacterial contamination

Pathogen inactivation of cellular components

Safest possible sources of donor for plasma products

FFP, fresh frozen plasma.

## Early

CONT. 1	
	toxicity
TARREST STREET	10.10.00.00.00
2001001200000	CONTRACTOR OF
	- 60

Hyperkalaemia

Hypocalcaemia(infants, massive transfusion)

Clotting abnormalities (after massive transfusion)

Transfusion-related acute lung injury (TRALI)

Post-transfusion purpura

Anaphylaxis (in IgA deficient subjects)

## Table 30.9 Complications of blood transfusion.

Early	Late
Haemolytic reactions: immediate (IgM) or delayed (IgG)	Transmission of infection (see Table 30.7)
Reactions caused by infected blood	Transfusional iron overload (see Chapter 4)
Allergic reactions to white cells, platelets or proteins	Immune sensitization, e.g. to red cells, platelets or Rh D antigen
Pyrogenic reactions (to plasma proteins or caused by HLA antibodies)	Transfusion-associated graft-versus-host disease Solution:
Circulatory overload	irradiation
Bacterial contamination	
Air embolism	
Thrombophlebitis	

## Management of Transfusion Reactions

- The first action is always to stop the transfusion and clarify that the correct patient's details are on the component being transfused.
- Any suspicion of ABO incompatibility should lead to the institution of circulatory support with IV fluids, careful monitoring of pulse, blood pressure and urine output, and supportive management of any developing DIC.
- ▶ The component bag should be returned to the transfusion laboratory with a fresh cross-match sample from the patient.
- ➤ Samples should also be sent to assess for intravascular hemolysis including a full blood count, serum haptoglobin, and hemoglobinuria.
- ▶ It is important to ensure that the possibility of bacterially contaminated units has been addressed through taking blood cultures.

#### cont'd...

- ▶ If necessary, broad-spectrum antibiotics may be commenced empirically after cultures have been drawn.
- ▶ Severe allergic reaction should be treated initially by stopping the transfusion and returning the unit to the laboratory.
- ► Chlorpheniramine may help, but severe reactions are likely to require oxygen and nebulized salbutamol, plus intramuscular adrenaline in the case of circulatory collapse.
- ▶ With mild fevers only, simple interventions may suffice (e.g. giving an antipyretic and slowing the transfusion); similarly, if a mild allergic reaction is evident (e.g. urticaria), chlorpheniramine followed by a slower reinstatement of the transfusion may help.
- ▶ Appropriate investigations include a full blood count, a direct antiglobulin test, serum bilirubin and assessment of renal function.

## Massive transfusion

- > Patients with acute hemorrhage (i.e. loss of red cells and plasma) may need to be transfused with large quantities of packed red cells.
- Massive transfusion has been defined as the replacement of one blood volume over 24 hours, or as the replacement of 50% of circulating volume in 3 hours.
- With the transfusion of many units of packed red cells, the patient may become deficient in key plasma components such as clotting factors and may also become thrombocytopenic (even in the absence of DIC).
- ➤ The administration of one unit of FFP per unit of red cells may be effective in replacing clotting factors. Fibrinogen and platelets should also be replaced, with 2 pools of cryoprecipitate and 1 adult dose of platelets per 6-8 units of packed red cells.

# Always Quality First;

#### Contents



Prefa	ceix
	Q U A L I T Y I S S U E S
1.	Quality Management Systems: Theory and Practice 1
	Tania L. Motschman, MS, MT(ASCP)SBB, CQA(ASQ); Betsy W. Jett, MT(ASCP), CQA(ASQ)CQM/OE; and Susan L. Wilkinson, EdD, MS, MT(ASCP)SBB
	Concepts in Quality
2.	Facilities, Work Environment, and Safety
	Betsy W. Jett, MT(ASCP), CQA(ASQ)CQM/OE; Susan L. Wilkinson, EdD, MS, MT(ASCP)SBB; and Tania L. Motschman, MS, MT(ASCP)SBB, CQA(ASQ)
	Facilities         40           Safety Program         42

### Conclusion:

- The main goal of blood bank services is to provide a safe blood component in timely and cost-effectiveness manners.
- Different key dedicated areas in the blood bank serve in harmony to achieve the main goal.
- ▶ Always, there is a risk in transfusion. All implemented standards goal to minimize the risk.
- ► Always, maintain the quality!

# Thank You!!!

# Example MCQs

- Which one of the following services is not under the donation sector of the blood bank?
  - A) Collection of whole blood unit.
  - ▶ B) Reconfirmation of donor blood group.
  - C) Component separation.
  - D) Infectious agents testing.
  - ▶ E) All services are belong the donation sector.





#### HEALTH Check QUESTIONNAIRE

Please respond by placing a 🗸 in the relevant box. Do not circle.

ASSESSED AND THE PROPERTY OF T		
1. Are you feeling well and healthy today?	YES [	NO
2. Did you eat well in the last 3hours?	YES	NO
3. Did you sleep well? YES NO .How many hours did you sleep for the last	24	
hours?		
4. Are you Currently taking an antibiotic?	YES	NO
5. Are you Currently taking any other medication ? YES NO What ?		
6.Have you read the educational materials?	YES [	NO
7. Since last week have you had any dental surgery?	YES	NO
8. Have you ever been rejected as a blood donor ? YES NO If yes why	?	
9. In the past 72 hours Have you taken aspirin or anything that has aspirin in it?	YES	NO
# In the past 8 weeks have you:		
10. Donated blood?	YES	NO
11. Had contact with someone who had a smallpox vaccination?	YES	NO
# In the past 16 weeks:		
12. Have you donated a double unit of red cells using an apheresis machine?	YES	NO
13. Had any vaccinations or other shots?	YES	NO
# In the past 12 months have you:		
14. have you had surgery or sever illness ?	YES	NO
15. have you or your spouse received blood or blood components?	YES	NO
16. Had a transplant such as organ, tissue, or bone marrow?	YES	NO
17. Had an accidental needle-stick?	YES	NO
18. Had sexual contact with anyone who has HIV/AIDS or has had a positive test	Davids	
for the HIV/AIDS virus or hemophilia or has used clotting factor concentrates?	YES	NO
19. Had sexual contact with a person who has hepatitis?	YES	_ NO
20. Ever been I.V. drug user, or used intranasal cocaine'?	YES	□ NO
21. Lived with a person who has hepatitis, HIV/AIDS or has had a positive test for		
the HIV/AIDS?	YES	NO
22. Had a tattoo, acupuncture, hejama, ear or body piercing?	YES	NO
23. Had or been treated for syphilis or gonorrhea?	YES	☐ NO
24. Been in juvenile detention or prison for more than 72 hours?	YES	NO
25. Been outside the Kingdom of Sauidi Arabia?	YES	NO
26. been given rabies shots ?	YES	NO
27. had any medical investigations or tests (including endoscopy)?	YES	NO

28. Did you spend time that adds up to six (6) months or more in the U 29. Spend time that adds up to five (5) years or more in Europe?	YES	NO	
	YES	NO	
30. Receive a blood transfusion in the United Kingdom or France?  # Have you EVER:		YES	NO
31. Had a positive test for the HIV/AIDS virus?		YES	NO
32. Used needles to take drugs, steroids, or anything not prescribed b	YES	NO	
33. Received a dura mater (or brain covering) graft?	YES	NO	
34. Had a graft such as bone , skin or cornea?		_	
35. Come into contact with someone else's blood?	YES [	NO	
36. Had jaundice or hepatitis?		YES	NO
37. Had a serious illness or seen a doctor about your heart?		YES [	NO
38. Had any type of cancer, including leukemia?		YES [	NO
		YES	NO
<ol> <li>Had growth hormone, Or injected with beef insulin?</li> <li>Any of your relatives had Creutzfeldt-Jakob disease [ Cow – madr</li> </ol>	!: 10	YES YES	NO
43 If you suffer or have you suffered from one of these diseases pleas the relevant box: Severe loss of weight			
43 If you suffer or have you suffered from one of these diseases pleas the relevant box:  Severe loss of weight  Syphilis  Enlarged glands  Unexplained weight loss  Heart Disease  Diabetes	ise respond by p	placing a	ease
Severe loss of weight  Syphilis Prolonged fever or diarrhea As Enlarged glands Allergy Mi Unexplained weight loss Skin disease Ja Heart Disease Diabetes Le Bleeding abnormalities Chaga's disease Al Epilepsy Lung disease St  44. To be answered by women only.	sthma   lalaria   aundice   eishmaniasis	Gonorrhe Hepatitis Brucellos Blood dis	ea is ease isease
43 If you suffer or have you suffered from one of these diseases please the relevant box:  Severe loss of weight  Syphilis  Enlarged glands  Unexplained weight loss  Heart Disease  Bleeding abnormalities  Chaga's disease  Brilepsy  As A	ssthma	Gonorrhe Hepatitis Brucellos Blood dis Kidney di Others:	ea is ease isease

#### MEDICAL EXAMIANTION by blood bank staff

General Condition:	Donor He	eight cm	Donor Weig	ht Kg
Temp.: °C	Pulse :	/min.	*B.P	m.m Hg
Accept	Defer	Permen	ant	Temporary
Cause of rejection		E Meig galako	r mister (or brain c	mit is headlecool.
Recall Date:		Sasmon.	se bone , skie er	ale sing a list.
Remarks			neutropet.	so soloturi, bri F
Physician Name:		Signature:	Date:	1 1
	CHECK	UP SCREENIN	G	
Capillary *Hb. level	g/dl	☐ Male	☐ Fen	nale
Blood group if applicable:	ocanic esance	rom one of these di	ave you suffered to	l se rolles-devit
Accept			Reject	devere less of
		Signature:	1 1	
Technician Name:		oigilataro.	Date:	
Technician Name:		) COLLECTION		Tayase ID hayly Talesding apnom
Technician Name:	BLOOE		sad [ ]	erse reactions
Lecestr health. I pleaten	BLOOE	) COLLECTION	sad [ ]	erse reactions
☐ Complete	BLOOD Discontinu	) COLLECTION	I Adve	ungwent ad 4 k
Complete Type of reaction	BLOOD Discontinu	O COLLECTION ed Product	I Adve	ungwent ad 4 g
Complete  Type of reaction  *V.P. Time start: AM	BLOOD Discontinu	O COLLECTION ed Product	Adve	ungwent ad 4 g





#### استمارة التبرع بالدم تسجيل المتبرع

Donor No.:	(tages)	Date:	V.	ine the same in	Unit f	No. :
		Do	nor Name	أسمالمتبرع		
First Name:	Father Name:	tay jake	AT .	Middle Name:		Family Name:
العائلة:		t Freez	الجد:		الأب:	الاسم الأول:
	برع	مكان اثت				تاريخ آخر تبرع
Statement of the Page	44.00		LEGO!			نتيجة آخر تبرع
a. s. Mallant		الجنسية		انثی	کر	الجنس الجنس
	سنة	العمر		محل الميلاد		تاريخ الميلاد
				رقم	ا إقامة	_ جواز _ بطاقة أحوال
W. C. Sandalia and Physics						اثعنوان
				رقم الهاتف		جوال
			-			البريد الالكتروني
		Reso	n of Dona	سببالتبرع tion		
متطوع 🗌 Volunteer		Therap	peutic [	علاجي [	Re	موجه لمريض 🔲 placement
داتي 🗌 Autologous		Driving Li	icense	استخراج رخصة [		
Patient File No.:	CONTRACTOR DE LA CONTRA	nothing and the second				رقم ملف المريض:
Whale bla		THE PROPERTY OF THE PARTY OF TH	pe of don	نوع التبرع ation	Diet	elets Aphaeresis 🗍 صفائح
Whole blo-		وحدة كاملا الدم الحمدا	من خلايا	وحدة مزدوجة		صفائح 📗 elets Aphaeresis. بلازما 🦳 ma Aphaeresis
Automated Bodble 14: B				ر. ده البيانات في أول زي		ma / pridorecio 🗀 = 52 ;
📗 لا أعرف			A 🗌	نعم 🗌	Aug 17 (17 (17 (17 (17 (17 (17 (17 (17 (17	هل سبق أن نقل لك دم طوال حب
						الوظيفة الحالية
بريد الإلكتروني مالة SMS 📗 لاشيء		الجوال	اب [ س <i>ن</i> [		كيرك للتبر	ما هي الوسيلة التي تفضلها لتذ
	نوقيع	וני				موظف الاستقبال



#### التاريخ الصحي للمتبرع

#### ضع علامة ٧ في المربع المناسب الإجابتك

انعم الا	١. هل تشعر بأنك بصحة جيدة اليوم؟
نعم 🔃 لا	٢. هل تناولت أي مأكولات خلال الثلاث الساعات السابقة؟
	٣. هل أخدت قسطاً وافراً من النوم ؟ 🔃 نعم 🔃 لا كم ساعة نمت خلال ٢٤ ساعة الماضية؟
نعم 🔲 لا	٤. هل تأخذ حاليا أي مضادات حيوية ؟
	ه. هل تأخذ أي علاج الآن؟ 🗌 نعم 📗 لا 🏿 إذا كان نعم فماهو ؟
نعم 📗 لا	٦. هل قرأت المطويات التعليمية (النشرات) التعليمة؟
نعم 🔃 لا	٧. هل أجريت لك جراحة بالأسنان خلال الأسبوع الماضي؟
	٨. هل سبق رفضك كمتبرع بالدم؟ 🗌 نعم 📗 لا المذا؟
نعم 🔃 لا	٩. خلال الـ ٧٧ ساعة السابقة للتبرع هل أخذت أسبرين أو أي دواء يحتوي على أسبرين؟
	# خلال الـ ٨ أسابيع ( شهرين) السابقة للتبرع:
نعم 🔲 لا	١٠. هل تبرعت بالدم؟
نعم 🗌 لا	١١. هل خالطت شخصاً قد أخذ تطعيم الجدري؟
	# خلال الـ ١٦ أسبوعاً ( ٤ أشهر تقريبا) السابقة للتبرع:
نعم 🔃 لا	١٢. هل تبرعت بوحدة دم مزدوجة بأستخدام جهاز فصل الخلايا؟
نعم 🔲 لا	١٣. هل أخذت أياً من التطعيمات أو أي نوع من الحقن؟
	# خلال الـ ١٢ شهراً السابقة للتبرع:
نعم 📗 لا	١٤. هل أجريت لك عملية جراحية؟ أو عانيت من مرض شديد؟
نعم 📗 لا	ه١٠. هل نقل لك دم أو أي من مشتقاته؟ (زوجك/زوجتك)؟
ا نعم 📗 لا	١٦. هل لامست دم شخص آخر؟
نعم 🔲 لا	١٧. هل سبق وخزك بإبرة عن طريق الخطأ؟
نعم 📗 لا	١٨. هل ( زوجتك/زوجك ) مريض بالهيموفيليا أو (تأخذ/يأخذ) عوامل التجلط؟
نعم لا	١٩. هل كانت هناك أيه علاقة جنسية غير شرعية؟ أومع مريض بالالتهاب الكبدي؟
ا نعم الا	٢٠. هل كنت تتناول المخدرات عن طريق الحقن أو تستنشق كوكايين؟
ا نعم الا	٢١. هل خالطت شخصاً مصاباً بالالتهاب الكبدى الفيروسي (باء) أو (سي) ؟
نعم 📗 لا	٢٢. هل خالطت شخصاً مصاباً بمرض الإيدز؟
نعم لا	٢٣. هل عملت وشماً أو حجامة أوعولجت بالإبر الصينية أو أجريت ثقباً للأذن أو ثقباً للجلد؟
نعم الا	٢٤. هل عولجت أو تعالج حاليا من السيلان أو الزهري؟
نعم 📗 لا	٢٥. هل كنت مسجوناً لأكثر من ٧٢ ساعة؟
جابة نعمأين ؟	٢٦. هل سافرت خارج المملكة العربية السعودية خلال العام الماضي؟ 🔃 نعم 🔃 لا إذا كانت الا
	ومتى ؟
نعم 📗 لا	٢٧. هل أخذت علاجاً بالحقن لمرض الكلب خلال العام الماضي؟
ا نعم 📗 لا	.٢٨. هل أجريت أي فحوصات طبية (بما في ذلك المناظير) ؟

attachers are a	# المدة من ١٩٨٠م وحتى الآن:
نعم لا	٢٠. هل أقمت في إنجلترا لمدة أشهر أو أكثر؟
انعم الا	٣٠. هل أمضيت فترة أكثر من ٥ سنوات في أوروبا؟
انعم الا	٣١. هل أخذت دماً أو أحد مشتقاته في بريطانيا (المملكة المتحدة) أو فرنسا ؟أو في أي بلد خارج المملكة؟
	# هل كان عندك قبل ذلك (طوال حياتك)؛
انعم الا	٣١. نتيجة إيجابية لمرض نقص المناعة ( الإيدز )؟
انعم الا	٣٢. هل أجريت لك عملية جراحية بالمخ لزراعة غشاء الديورا؟
انعم الا	٣٤. هل زرعت لك أعضاء أو أنسجة أو نخاع ؟
انعم الا	٣٥. هل أجرى لك ترقيع للجلد أو للعظام أو للقرنية؟
انعم ا	٣٠. هل كان لديك يرقان (صفراء) أو إلتهاب كبدي؟
انعم الا	٣١. هل كان لديك مرض شديد أجريت فحصاً لقلبك بواسطة طبيب؟
انعم	٣/. هل أصبت بأي سرطان بما في ذلك اللوكيميا؟
انعم ا	٣٠. هل أخذت حقن أنسولين بقري ؟ أو هرمون النمو؟
انعم الا	٤. هل أصبت أو أحد أفراد أسرتك بمرض جنون البقر؟
	ع علامة 🗸 إذا كان لديك هذا المرض:
راض النزف بو شعبي مى مالطية ي أمراض أخرى	تقص شديد قي الوزن بدون أسباب الرتفاع بالحرارة أو إسهال مستمر لفترة طويلة الإيدز الا مرض السكري المصدي الشما نيا أمراض بالدم أم المرف الدماغ أو نزيف بالمخ مرض بالقلب مرض بالرئتين الدرن ررا المسلان الصرع مرض بالكلى حساسية الملا ريا حياقان مرض شاجاز مرض جلدي (صدفية، بهاق، حزاز، أكزيماالخ) أو
راض النزف بو شعبي مى مالطية ي أمراض أخرى	قص شديد في الوزن بدون أسباب الرتفاع بالحرارة أو إسهال مستمر لفترة طويلة الإيدز الا مرض السكري المضعم بالغدد الشما نبا أمراض بالدم أم المحلة الدماغ أو نزيف بالغ مرض بالقلب مرض بالرئتين الدرن ربا السرع مرض بالكلى حساسية اللاريا حوال المرض شاجاز مرض جلدي (صدفية، بهاق، حزاز، أكزيماالخ) أو كلانات: (أ) خلال الستة الأسلبيع الأخيرة:  عل كنت حاملاً؟ انعم الا أو وضعتي مولودا ؟ انعم الا أو وضعتي مولودا ؟ انعم الا
بو شعبي می مالطیة پی اُمراض آخری ک فیات الجامعیا	تقص شديد في الوزن بدون أسباب الرتفاع بالحرارة أو إسهال مستمر لفترة طويلة الإيدز الا مرض السكري مرض السكري تضخم بالغدد الشما نيا المراض بالدم أم المحلة الدماغ أو نزيف بالمخ مرض بالقلب مرض بالرئتين الدرن روا المسلان الصرع مرض بالكلى احساسية الملا ريا حال المرقان مرض شاجاز مرض جلدي (صدفية، بهاق، حزاز، أكزيماالمخ) أو . للإناث: (أ) خلال الستة الأسابيع الأخيرة :

شكرا لحضورك للتبرع اليوم

#### خاص بالعاملين ببنك الدم

General Condition:	Donor Hei	ght cm	Donor Weight K
Temp.: °C	Pulse :	/min.	*B.P m.m H
Accept D	efer	Permen	ant Temporary
Cause of rejection	lo E		
Recall Date:			
Remarks	one I fisher to be a	la discont	
Physician Name :	Sign	ature:	Date: / /
	CHECK UP	SCREENIN	G
Capillary *Hb. level g/dl		Male	Female
Blood group if applicable:			
Accept			Reject
Technician Name:	Sign	ature:	Date: / /
	BLOOD C	OLLECTION	I
Complete	Discontinued F	Product	Adverse reactions
Type of reaction			
*V.P. Time start:	☐ PM -	*V.P. Time end	: AM PM,
Unit Volume:			
Blood Bag Lot No.:		Expired	Date:
Technician Name:	Sign	nature:	Date: / /
Key: * B.P. = Blood Pressure.	* Hb. = Her	noglobin	* V.P. = Venipuncture.
	TIO. TICI		v.r. – veriipuricture. مطابع جامعة الملك سعود